Compare APLS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLS | TWST |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2017 | 2018 |
| Metric | APLS | TWST |
|---|---|---|
| Price | $23.49 | $49.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | $32.16 | ★ $50.22 |
| AVG Volume (30 Days) | ★ 3.9M | 1.5M |
| Earning Date | 02-27-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,016,397,000.00 | $391,557,000.00 |
| Revenue This Year | $31.31 | $16.77 |
| Revenue Next Year | N/A | $15.06 |
| P/E Ratio | $65.59 | ★ N/A |
| Revenue Growth | ★ 42.11 | 18.59 |
| 52 Week Low | $16.10 | $23.30 |
| 52 Week High | $30.53 | $54.74 |
| Indicator | APLS | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 70.96 |
| Support Level | $22.29 | $44.91 |
| Resistance Level | $24.10 | $48.73 |
| Average True Range (ATR) | 1.18 | 2.57 |
| MACD | 0.15 | 0.32 |
| Stochastic Oscillator | 76.65 | 91.89 |
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.